Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
candesartan + metformin
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of two separate medications: candesartan, an angiotensin receptor blocker (ARB) primarily used to treat hypertension (high blood pressure), and metformin, an antihyperglycemic agent used to treat type 2 diabetes by improving glucose tolerance and lowering both basal and postprandial plasma glucose levels. This combination is not a single formulated product but represents concurrent use of these medications.
02
Targets
GSK3 (Glycogen synthase kinase 3 beta)ND1 (Mitochondrial electron transport chain complex I)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on candesartan + metformin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on candesartan + metformin.